Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma

Clinical Genitourinary Cancer

Volumn 7, Issue 3, 2009, Pages

  Vickers, Michael M ^a   Heng, Daniel Y ^a   Hemmelgarn, Brenda ^b   Eigl, Bernhard J ^a  

^a TOM BAKER CANCER CENTRE   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Hemodialysis; Peritoneal dialysis; Tyrosine kinase inhibitor; Vascular endothelial growth factor

Indexed keywords

AMLODIPINE; CLONIDINE; ENALAPRIL; METOPROLOL; RAMIPRIL; SUNITINIB; TEMSIROLIMUS; THYROXINE;

ADULT; AGED; ARTICLE; CANCER STAGING; CASE REPORT; CLEAR CELL CARCINOMA; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG DOSE INCREASE; DRUG TOLERANCE; FATIGUE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; LIVER METASTASIS; LUNG METASTASIS; LYMPHADENOPATHY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PERITONEAL DIALYSIS;

EID: 70449125888     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2009.n.035     Document Type: Article

References (14)

1. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124 (Pubitemid 46089672)
2. Izzedine H, Etienne-Grimaldi MC, Renée N, et al. Pharmacokinetics of sunitinib in hemodialysis. Ann Oncol 2009; 20:190-192
3. Reckova M, Kakalejcik M, Beniak J. Treatment of hemodialyzed patient with sunitinib. Ann Oncol 2009; 20:392-393
4. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24:25-35.
5. Agarwal R, Nissenson AR, Batlle D, et al. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the united states. Am J Med 2003; 115:291-297
6. Rocco MV, Flanigan MJ, Beaver S, et al. Report from the 1995 Core Indicators for Peritoneal Dialysis Study Group. Am J Kidney Dis 1997; 30:165-173
7. Jhamb M, Weisbord SD, Steel JL, et al. Fatigue in patients receiving maintenance dialysis: a review of definitions, measures, and contributing factors. Am J Kidney Dis 2008; 52:353-365
8. Pfizer. Sutent (Sunitinib) Prescribing information, 2007. Available at: http:// media.pfizer.com/files/products/uspi-sutent.pdf. Accessed: January 21, 2009.
9. Telli ML, Witteles RM, Fisher GA, et al. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 2008; 19:1613-1618
10. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008; 26:5204-5212
11. Collins AJ. Cardiovascular mortality in end-stage renal disease. Am J Med Sci 2003; 325:163-167
12. Houk BE, Bello CL, Michaelson MD, et al. Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/ pharmacodynamic (PKPD) approach. J Clin Oncol 2007; 25(suppl):241s (Abstract 5027).
13. Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the united states renal data system 2004 annual data report: Atlas of end-stage renal disease in the united states. Am J Kidney Dis 2005; 45(1 suppl 1):A5-A7, S1-280.
14. Chow WH, Devesa SS. Contemporary epidemiology of renal cell cancer. Cancer J 2008; 14:288-301.